2022 July 7 release
brendanreardon
released this
07 Jul 17:28
·
27 commits
to main
since this release
Added entries:
- (FDA) BRAF p.V600E and sensitivity to dabrafenib in combination with trametinib in any solid tumor.
- (FDA) IDH1 p.R132C, p.R132H and sensitivity to ivosidenib either with azacitidine or as a monotherapy in acute myeloid leukemia.
- (FDA) MSI-H and sensitivity to pembrolizumab in endometrial carcinoma.